Evidence map›Paper›PMID 35142337›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Genital Immune Cell Activation and Tenofovir Gel Efficacy: A Case-Control Study.

Lenine J P Liebenberg, Jo Ann S Passmore, Farzana Osman, Janine Jewanraj, Andile Mtshali, J Gerardo Garcia-Lerma, Walid Heneine, Angela Holder, Derseree Archary, Sinaye Ngcapu and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Lenine J P LiebenbergCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.ORCID 0000-0001-6768-8776
Jo Ann S PassmoreCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Farzana OsmanCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Janine JewanrajCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Andile MtshaliCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
J Gerardo Garcia-LermaDivision of HIV/AIDS Prevention, National Center for HIV/ AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Walid HeneineDivision of HIV/AIDS Prevention, National Center for HIV/ AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Angela HolderDivision of HIV/AIDS Prevention, National Center for HIV/ AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Derseree ArcharyCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Sinaye NgcapuCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Aida SivroCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Leila E MansoorCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Quarraisha Abdool KarimCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Salim S Abdool KarimCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Lyle R McKinnonCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Centre for the AIDS Programme of Research in South Africa · ZACenters for Disease Control and Prevention · USNational Health Laboratory Service · ZA

Funding

Inflammation and HIV risk: understanding partial Tenofovir efficacy in CAPRISA004R01AI111936 · NIAID · CENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA · PI PASSMORE, JO-ANN SHELLEY · 2014 to 2017
$2.1M
NIAID NIH HHS R01 AI111936
6 · The paper itself

Abstract

Genital inflammation (GI) undermines topical human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) efficacy through unknown mechanisms. Here, associations between activated endocervical CD4 + T-cell numbers and higher deoxyadenosine triphosphate (dATP) concentrations suggest that competition for intracellular metabolites within HIV target cells may reduce the efficacy of antiretroviral-based PrEP in women with GI.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisCase-Control StudiesDeoxyadenosinesEmtricitabineFemaleGenitaliaHumansTenofovirAnti-HIV AgentsDeoxyadenosinesEmtricitabineTenofovirdATPgenital inflammationHIVimmune activationtenofovir

Identifiers

PMID35142337
PMCPMC9989354
OpenAlexW4210321193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.